All studies are using DehydraTECHâ„¢ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexaria's 2021 applied R&D program intended to enable opportunities for strategic partnerships KELOWNA, BC / ACCESSWIRE / June 9, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX)… Read More..
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the formation of its Clinical Advisory Committee. Comprised of thought leaders in immunology, rheumatology, neurology, and nephrology, members of the committee will provide Kezar with strategic guidance and… Read More..
Facility Increases Company's Current Liquidity to Over $22 Million and Provides Flexibility to Aggressively Pursue its 7th Contemplated Acquisition, Reconfirm its Stock Repurchase Program, Broaden Record Label Music Licenses Globally, and Expand Live Music, Podcast and Original Program Line Ups Company Continues its Process to Explore Strategic Alternatives in Order… Read More..